A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans

There is a need to improve antiretroviral options in Africa. This study shows switching from a neviripine-based treatment to co-formulated rilpivirine/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed Rwandans is safe and non-inferior to continued nevirapine-based therapy at 24 weeks.

[1]  J. van Lunzen,et al.  Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study , 2016, AIDS.

[2]  J. Eron,et al.  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. , 2015, The Lancet. Infectious diseases.

[3]  N. Ford,et al.  Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials , 2015, Journal of acquired immune deficiency syndromes.

[4]  C. Delaugerre,et al.  Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. , 2015, The Journal of antimicrobial chemotherapy.

[5]  M. Blonk,et al.  The Efficacy, Pharmacokinetics, and Safety of a Nevirapine to Rilpivirine Switch in Virologically Suppressed HIV-1–Infected Patients , 2015, Journal of acquired immune deficiency syndromes.

[6]  F. Raffi,et al.  Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. , 2014, The Journal of antimicrobial chemotherapy.

[7]  Michael I. Jordan,et al.  E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. , 2014, Antiviral research.

[8]  P. Sax,et al.  Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide , 2014, Annals of Internal Medicine.

[9]  A. Waldman,et al.  Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. , 2014, The Journal of antimicrobial chemotherapy.

[10]  R. Tubiana,et al.  Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11) , 2014, PLoS medicine.

[11]  P. Swamy,et al.  Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies , 2014, AIDS.

[12]  B. Gazzard,et al.  Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants , 2014, AIDS.

[13]  K. White,et al.  Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens , 2013, HIV clinical trials.

[14]  N. Ford,et al.  Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis , 2013, PloS one.

[15]  Edward J Mills,et al.  Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis , 2013, AIDS.

[16]  J. Ananworanich,et al.  Efavirenz, in Contrast to Nevirapine, is Associated With Unfavorable Progesterone and Antiretroviral Levels When Coadministered With Combined Oral Contraceptives , 2013, Journal of acquired immune deficiency syndromes.

[17]  D. Ward,et al.  Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION) , 2012, HIV medicine.

[18]  B. Clotet,et al.  Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis , 2012, Journal of acquired immune deficiency syndromes.

[19]  N. Ford,et al.  Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis , 2011, AIDS.

[20]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[21]  B. Clotet,et al.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial , 2011, The Lancet.

[22]  V. DeGruttola,et al.  Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana , 2010, AIDS.

[23]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[24]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[25]  I S Chan,et al.  Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions , 1999, Biometrics.